Market Research Logo

Antibody Discovery: Services and Platforms, 2017-2027

Antibody Discovery: Services and Platforms, 2017-2027

The rising demand of personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody based therapeutics. Antibodies, because of several advantages such as high specificity and targeted approach, are increasingly becoming crucial for the treatment of a number of diseases. In fact, since 2015, more than 20 antibodies have been approved by the USFDA. The growing popularity of antibody based therapeutics is also reflected from the dominance of these biologics in the portfolios of major biopharmaceutical companies.

At present, the focus of majority of biopharmaceutical companies is on discovering therapeutic antibodies against novel targets. However, discovery of antibodies is a long, arduous and costly process; as a result, there is a growing preference to outsource such operations. Drug developers are partnering with contract research organizations (CROs) that provide antibody discovery services using novel and advanced technologies. Outsourcing enables biopharmaceutical companies / academic institutes accelerate their drug discovery process by leveraging the technical capabilities and expertise of CROs. Additionally, a number of drug developers and academic institutes have obtained rights to access novel antibody discovery platforms from technology providers. As the demand of novel therapeutic antibodies for various disease areas is expected to rise steadily, we are optimistic about the future of the contract research firms that are driving innovation in the drug discovery process.

SCOPE OF THE REPORT
The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and platform providers. The study presents an in-depth analysis of a diverse set of companies that provide antibody discovery services and / or provide access to their platforms to drug developers. In addition to other elements, the report provides information on the following:

The competitive market landscape and industry analysis with respect to key players along with information on their geographical location, type of business operation, methods used for antibody generation and the purpose of antibody discovery (therapeutic and / or diagnostic).

Elaborate profiles of established / emerging players that offer a wide range of services in the overall antibody discovery process; each profile includes a brief overview of the company, information on its financial and funding details (if available), antibody discovery service portfolio and novel antibody discovery technology / platforms, and a view on its future outlook and strategy.

Most active regions in terms of antibody discovery services and platforms; the report contains schematic representations of world maps that clearly indicate the location of antibody discovery service hubs.

Platform competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of antibody discovery platforms that are available for licensing.

A case study covering detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies such as Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®.

Partnerships that have taken place in the recent past covering research collaborations, service agreements, license agreements, mergers / acquisitions and other deals signed between industry / non-industry stakeholders.

The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the antibody discovery services market. We have provided insights on the likely evolution of the market in different regions including North America, Europe, China and rest of the world. In addition, we have provided the likely evolution on the basis of the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (chimeric, humanized and fully human). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 60 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).

EXAMPLE HIGHLIGHTS
1. During the course of our study, we identified more than 60 companies that offer antibody discovery services. Majority (more than 80%) of these antibody discovery service providers are located in North America and EU. Examples of the players based in these regions include (in alphabetical order) Adimab, Aragen Bioscience, Antibody Solutions, Evotec, GenScript, Integral Molecular, ModiQuest Research and PX'Therapeutics.

2. It is worth highlighting that a number of start-ups have entered this domain to provide contract research services; examples include (in alphabetical order) Ab Studio, Abveris Antibody, AffinityImmuno, ChemBio Discovery Solutions, G&P Biosciences, HiFiBiO, OriMAbs, Panoply Bio and Specifica.

3. CROs offer antibody discovery services by deploying a variety of methods such as library based (phage display, yeast display and mammalian display), hybridoma, transgenic animal based and single cell based methods. During our research, we observed that a vast majority of companies (31) offer antibody discovery services by using library based methods. This is followed by companies that use hybridoma method (27), single cell based methods (13) and transgenic animal based methods (11).

4. Companies that have developed novel antibody drug discovery platforms are providing access / non-exclusive licenses of their proprietary platforms to drug developers, CROs and academic institutes. During the course of our study, we identified more than 20 such platform providers. Around 40% of the antibody discovery platform providers are headquartered in North America, 36% of companies are based in Europe while the remaining (24%) are located in the Asia Pacific region.

5. Majority (13) of the platforms available for licensing are library based; examples include Abtracer™, ADAPT™, ADLib® library, mAbLogix™ and n-CoDeR® antibody library. There are seven transgenic animal based platforms that are available for licensing; these include AlivaMab™ Mouse, Kymouse™ platform, OmniAb® platforms and TRIANNI Mouse platform.

6. A number of stakeholders in the field of antibody discovery have entered into collaborations with CROs and / or technology providers. We came across 172 deals that have been signed during the period 2011-2017. Majority (~50%) of the partnerships in this domain are research collaborations; this highlights the fact that extensive research is being conducted to discover novel therapeutic antibodies. Technology licensing is the second most popular partnership model in this field, capturing 32% share. Prominent contract service providers that have entered into multiple partnerships include Adimab, Crystal Biosciences, MAB Discovery, AbCellera and Abzena.

7. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to witness continuous growth in the coming decade. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; we believe that China is likely to grow at faster rate (annualized rate of 8.9%) as compared to other regions in the coming decade. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate (annualized rate of 6.6%) as compared to the established methods such as phage display and hybridoma methods.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.

Chapter 3 provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, such as polyclonal, monoclonal and bispecific antibodies.

Chapter 4 features information on the antibody discovery process and the various antibody discovery methods. It also includes a comparison of the different antibody discovery methods that are available currently. Additionally, the chapter provides insights on the gradual shift in development trends for monoclonal antibodies over the last three decades, from fully murine to fully human variants.

Chapter 5 includes a comprehensive landscape of the companies that offer antibody discovery services and / or provide licenses to their antibody discovery platforms. For the antibody discovery service providers, the chapter includes analyses on the basis of their geographical location, type of business operations, methods used for antibody generation, steps involved in antibody discovery and purpose of antibody discovery (therapeutic and / or diagnostic). For antibody discovery platform providers, the chapter provides analysis based on geographical location and antibody generation methods on which the platforms are based. Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.

Chapter 6 provides detailed profiles of some of the players, based in different geographies, which are actively providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial and funding information (if available), details on antibody discovery services and novel antibody discovery technology / platforms, and a view on its future outlook and strategy.

Chapter 7 provides detailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, funding instances, financial information (if available), details on antibody discovery technology / platforms and a view on its future outlook and strategy. The chapter also presents 2 X 2 matrices, comparing competitiveness and supplier power of the antibody discovery platforms.

Chapter 8 presents a comprehensive view on how the antibody discovery services market is likely to grow over the next ten years. We have segregated the financial opportunity on the basis of different regions (North America, Europe, China and rest of the world), the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (murine, chimeric, humanized and fully human). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. The chapter also presents insightful 2 X 2 matrices to highlight the market share and market attractiveness derived from the current and likely future state of the market. Due to uncertainties surrounding some of the assumptions within our forecast model, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 9 features an elaborate discussion and analysis on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market.

Chapter 10 provides detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies. The antibodies for which details on discovery process and method are provided include Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®.

Chapter 11 presents insights from the survey conducted for this study. We invited over 60 stakeholders involved in providing antibody discovery services and platforms. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 12 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this market in the short and long term.

Chapter 13 is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).

Chapters 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1. 4-Antibody
2. ABBA Therapeutics
3. AbGenics Life Sciences
4. AbBioSci
5. AB Biosciences
6. Abbott Laboratories
7. AbbVie
8. AbCellera
9. AbCheck
10. Abgent
11. Abeome
12. Ablexis
13. Abpro
14. Ab Studio
15. Abveris Antibody
16. Abwiz Bio
17. Abzena
18. Abzyme Therapeutics
19. Accurus Biosciences
20. Acceleron Pharma
21. Achaogen
22. ACYTE Biotech
23. Adimab
24. Aduro Biotech
25. Advantech Capital
26. AffinityImmuno
27. Affitech
28. Agenus
29. Agilent Technologies
30. Aguettant Pharmaceutical
31. AIMM Therapeutics
32. Akeso Biopharma
33. Alcon
34. Aldevron
35. Alder BioPharmaceuticals
36. Alector
37. Alere
38. Alexion Pharmaceuticals
39. Ambrx
40. Amgen
41. Anaimmune
42. AnaptysBio
43. Antagene
44. Antitope
45. Antibody Solutions
46. AP Biosciences
47. Apexigen
48. Aragen Bioscience
49. arGEN-X
50. Aridis Pharmaceuticals
51. Aristi Biotech
52. AstraZeneca
53. Atreca
54. Austrianni
55. AvantGen
56. AxioMx
57. BASF Bioresearch Corporation
58. Baylor Scott & White Research Institute
59. Bayer Pharma
60. Bill & Melinda Gates Foundation
61. BioAtla
62. Biogen
63. BioInvent
64. Biolauncher
65. BioNTech
66. BioRap Technologies
67. BioSavita
68. BIOTEM
69. Bird Rock Bio
70. bluebird bio
71. Boehringer Ingelheim
72. Boston Children's Hospital
73. Brigham and Women’s Hospital
74. Bristol-Myers Squibb
75. Cambridge Antibody Technology
76. Cancer Research Technology
77. CDI Laboratories
78. Celgene
79. Cellectis
80. Centers for Disease Control and Prevention
81. Centocor Biotech
82. Charles River Laboratories
83. ChemBio Discovery Solutions
84. ChemPartner
85. Chiome Bioscience
86. Chugai Pharmaceutical
87. Chugai Pharmabody Research
88. CIS Bio
89. Commerce Health Capital
90. Compass Therapeutics
91. Compugen
92. ContraFect
93. CorMatrix
94. Corixa
95. Cosmo Pharmaceuticals
96. Creative Biolabs
97. Crelux
98. Crescendo Biologics
99. Cresset Biomolecular Discovery
100. Crucell
101. Crystal Biosciences
102. Cytogen
103. Daiichi Sankyo
104. Dako
105. Defense Threat Reduction Agency (DTRA)
106. DJS Antibodies
107. Digital Proteomics
108. Distributed Bio
109. Dyax
110. Effimune
111. Eight Roads Ventures
112. Elan
113. Eli Lilly
114. Elusys Therapeutics
115. Emergent BioSolutions
116. Enumeral
117. Epimab Biotherapeutics
118. Erasmus University Medical Center
119. Essex Bio
120. Eureka Therapeutics
121. Evotec
122. Exonbio
123. Exiris
124. FairJourney Biologics
125. Five Prime Therapeutics
126. Fred Hutchinson Cancer Research Center
127. French Institute of Health and Medical Research (INSERM)
128. Fresenius
129. Fusion Antibodies
130. G&P Biosciences
131. GeneFrontier Corporation
132. Genentech
133. Genmab
134. Genor Biopharma
135. GenScript
136. Genzyme
137. Georgia Institute of Technology
138. GigaGen
139. Gilead Sciences
140. GlaxoSmithKline
141. Grenoble Hospital
142. GVK BIO
143. Harbour Antibodies
144. Harbour BioMed
145. HD Biosciences
146. Henlix Biotech
147. Hepalink
148. Heptares Therapeutics
149. HiFiBiO - High Fidelity Biology
150. HitGen
151. HQL Pharmaceuticals
152. HUMABS BioMed
153. Human Genome Sciences
154. Ibex Biosciences
155. Icosagen
156. Igenica Biotherapeutics
157. ImClone Systems
158. Immune Biosolutions
159. Immunologix
160. Immunomic Therapeutics
161. Immunomedics
162. Immunome
163. IMAPAC
164. Immpact
165. In-Cell-Art
166. Innovent Biologics
167. Institute for Transplantation-Urology-Nephrology, Nantes, France
168. Institute of Immunology of the Centre de Recherche Public-Santé
169. Institut Pasteur
170. Integral Molecular
171. Intrexon
172. IONTAS
173. Isogenica
174. iTeos Therapeutics
175. Janssen Biotech
176. Jiangsu Hengrui Medicine
177. Johnson & Johnson
178. Johnson & Johnson Pharmaceutical Research & Development
179. Jounce
180. Kite Pharma
181. Kodiak Sciences
182. Knoll
183. Kymab
184. Kyowa Hakko Kirin
185. LakePharma
186. LAMPIRE Biological Laboratories
187. Legend Capital
188. Leland Stanford Junior University
189. Leiden University Medical Center
190. Les Laboratoires Servier
191. Life Sciences Fund Amsterdam
192. Ligand Pharmaceuticals
193. Lille Regional University Hospital Centre
194. MAB Discovery
195. MabSpace Biosciences
196. MabVax Therapeutics
197. Magenta Therapeutics
198. Maine Biotechnology Services
199. Malin Corporation
200. MassBiologics
201. Massachusetts General Hospital
202. Maverick Therapeutics
203. Medarex
204. MedImmune
205. Meditope Biosciences
206. Memo Therapeutics
207. Memorial Sloan Kettering Cancer Center
208. Merck Serono
209. Mersana Therapeutics
210. Merus
211. Millennium Pharmaceuticals
212. MimAbs
213. Mitsubishi Tanabe Pharma Corporation
214. ModiQuest Group
215. ModiQuest Research
216. Molcure
217. Molecular Templates
218. MorphoSys
219. MSM Protein Technologies
220. Nantes Centre for Research in Transplantation and Immunology
221. National Cancer Institute
222. National Institute of Allergy and Infectious Diseases (NIAID)
223. National Institute on Drug Abuse
224. NB Health Laboratory
225. NeoClone
226. NeoRX Corporation
227. Neurimmnne
228. NewSpring Capital
229. New York University (NYU)
230. North Coast Biologics
231. Novartis
232. Novimmune
233. Novo Nordisk
234. Numab
235. Olympic Protein Technologies
236. Oncobiologics
237. Oncothyreon
238. ONO PHARMACEUTICAL
239. Open Monoclonal Technology
240. Organon Teknica
241. ORI Healthcare Fund
242. OriMAbs
243. Ossianix
244. Oxford Biotherapeutics
245. OZYME
246. PacificGMP
247. Palatin Technologies
248. Panoply Bio
249. Pfizer
250. Ping An Bank
251. PolyTherics
252. Potenza Therapeutics
253. ProtTech
254. Paris Public Welfare Hospital
255. Public Investment Bank
256. PX'Therapeutics
257. QoolAbs
258. Quanta BioDesign
259. Queen Mary University of London
260. RayBiotech
261. Regeneron Pharmaceuticals
262. Research Corporation Technologies
263. Ribovax Biotechnologies
264. Roche
265. SAB Biotherapeutics
266. Sanofi Aventis
267. Sea Lane Biotechnologies
268. Seattle Genetics
269. Sevion Therapeutics
270. ShangPharma
271. Shenogen Pharma
272. Shenzhen Hepalink Pharmaceutical
273. Shire
274. Single Cell Technology
275. Singapore Immunology Network
276. Sobi
277. Soligenix
278. Specifica
279. SISCAPA Assay Technologies
280. Sutro Biopharma
281. Surface Oncology
282. Symphogen
283. Syngene
284. Synthetic Biologics
285. Synthon Biopharmaceuticals
286. Taconic
287. Takeda Pharmaceutical
288. Tanabe Research Laboratories
289. TeneoBio
290. Tetragenetics
291. Teva Respiratory
292. The Chemistry Research Solution (TCRS)
293. Theraclone Sciences
294. The Scripps Research Institute
295. The US Army Edgewood Chemical Biological Center
296. Tizona Therapeutics
297. TransGenic
298. Trellis Bioscience
299. TRIANNI
300. Trieza Therapeutics
301. Tri-Institutional Therapeutics Discovery Institute
302. UCB
303. United Therapeutics
304. University of Alabama
305. University of Amsterdam
306. University of California, Los Angeles
307. University of Texas Health Science Center
308. University Institute of Hematology, Paris
309. University of Southampton
310. University of Texas MD Anderson Cancer Center
311. University of Turku
312. University of Westminster
313. Vaccinex
314. Valeant Pharmaceuticals
315. Viva Biotech
316. Viventia Bio
317. Warburg Pincus
318. Warwick Effect Polymers
319. Wellcome Trust
320. Wellcome Trust Sanger Institute
321. Woodford Investment Management
322. Woodford Patient Capital
323. WuXi AppTec
324. WuXi Biologics
325. WuXi PharmaTech
326. Wyeth
327. XBiotech
328. XOMA Corporation
329. YUMAB


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION TO ANTIBODIES
3.1. Chapter Overview
3.2. Historical Background of Antibodies
3.3. Structure of Antibodies
3.4. Isotypes of Antibodies
3.5. Mechanism of Action of Antibodies
3.6. Polyclonal and Monoclonal Antibodies
3.7. Bispecific Antibodies
3.8. Applications of Antibodies
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In Vitro Display Methods
4.3.2.1. Phage Display Method
4.3.2.2. Yeast Display Method
4.3.2.3. Ribosomal Display Method
4.3.3. Transgenic Animals Based Method
4.3.4. Single B cell Based Method
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies: From Murine to Fully Human
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Services Providers: Overall Market Landscape
5.2.1. Antibody Discovery Services Providers: Analysis by Business Operation
5.2.2. Antibody Discovery Services Providers: Analysis by Steps Involved in Antibody Discovery
5.2.3. Antibody Discovery Services Providers: Analysis by Antibody Generation Methods
5.2.4. Antibody Discovery Services Providers: Analysis by Purpose of Antibody Discovery
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Antibody Discovery Platform Providers: Analysis by Antibody Generation Methods
5.4. Antibody Discovery Platforms Used for In-house Purposes
6. ANTIBODY DISCOVERY SERVICES PROVIDERS
6.1. Overview
6.2. Antibody Discovery Services Providers: North America
6.2.1. Abwiz Bio
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Antibody Discovery Services
6.2.1.4. Antibody Discovery Platforms
6.2.1.4.1. Needle-in-a-Haystack Technology™
6.2.1.4.2. RabWiz™
6.2.1.4.3. WizAmp™
6.2.1.5. Recent Developments
6.2.1.5.1. Partnerships
6.2.1.6. Future Outlook
6.2.2. Aragen Bioscience (A GVK BIO Company)
6.2.2.1. Company Overview
6.2.2.2. Antibody Discovery Services
6.2.2.3. Recent Developments
6.2.2.3.1. Expansions
6.2.2.3.2. Partnerships
6.2.2.4. Future Outlook
6.2.3. LakePharma
6.2.3.1. Company Overview
6.2.3.2. Antibody Discovery Services
6.2.3.3. Recent Developments
6.2.3.3.1. Expansions
6.2.3.3.2. Partnerships
6.2.3.4. Future Outlook
6.3. Antibody Discovery Service Providers: Europe
6.3.1. Abzena
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Antibody Discovery Services
6.3.1.4. Recent Developments
6.3.1.4.1. Expansions
6.3.1.4.2. Partnerships
6.3.1.5. Future Outlook
6.3.2. ModiQuest Research (Subsidiary of ModiQuest Group)
6.3.2.1. Company Overview
6.3.2.2. Antibody Discovery Services
6.3.2.3. Antibody Discovery Platforms
6.3.2.3.1. ModiVacc™: Proprietary Hyper-Immune Stimulatory Cell Immunization Platform
6.3.2.3.2. ModiFuse™: Proprietary Hybridoma Platform
6.3.2.3.3. ModiSelect™: Proprietary B Cell Selection Platform
6.3.2.3.4. ModiPhage™: In-House and Custom Phage Libraries
6.3.2.3.5. ModiTune™: Antibody Optimization Platform
6.3.2.3.6. ModiXpress™: Proprietary In-House Expression Platform
6.3.2.4. Recent Developments
6.3.2.4.1. Partnerships
6.3.2.5. Future Outlook
6.3.3. PX'Therapeutics (a Subsidiary of Aguettant Pharmaceutical Group)
6.3.3.1. Company Overview
6.3.3.2. Antibody Discovery Services
6.3.3.3. Recent Developments
6.3.3.3.1. Partnerships
6.3.3.4. Future Outlook
6.4. Antibody Discovery Service Providers: Asia Pacific
6.4.1. ChemPartner
6.4.1.1. Company Overview
6.4.1.2. Antibody Discovery Services
6.4.1.3. Recent Developments
6.4.1.3.1. Expansions
6.4.1.3.2. Partnerships
6.4.1.4. Future Outlook
6.4.2. Viva Biotech
6.4.2.1. Company Overview
6.4.2.2. Antibody Discovery Services
6.4.2.3. Recent Developments
6.4.2.3.1. Partnerships
6.4.2.4. Future Outlook
6.4.3. WuXi AppTec
6.4.3.1. Company Overview
6.4.3.2. Financial Information
6.4.3.3. Antibody Discovery Services
6.4.3.4. Recent Developments
6.4.3.4.1. Expansions
6.4.3.4.2. Partnerships
6.4.3.5. Future Outlook
7. ANTIBODY DISCOVERY PLATFORM PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Platform Providers: North America
7.2.1. Ligand Pharmaceuticals
7.2.1.1. Company Overview
7.2.1.2. Financial Information
7.2.1.3. Antibody Discovery Platforms
7.2.1.3.1. OmniAb®
7.2.1.3.1.1. OmniRat®
7.2.1.3.1.2. OmniMouse®
7.2.1.3.1.3. OmniFlic®
7.2.1.4. Patent Portfolio
7.2.1.5. Recent Developments
7.2.1.6. Future Outlook
7.2.2. TRIANNI
7.2.2.1. Company Overview
7.2.2.2. The TRIANNI Mouse™ Platform
7.2.2.3. Patent Portfolio
7.2.2.4. Recent Developments
7.2.2.5. Future Outlook
7.3. Antibody Discovery Platform Providers: Europe
7.3.1. AIMM Therapeutics
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. AIMSelect™
7.3.1.4. Recent Developments
7.3.1.5. Future Outlook
7.3.2. Kymab
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Kymouse™
7.3.2.4. Patent Information
7.3.2.5. Recent Developments
7.3.2.6. Future Outlook
7.4. Antibody Discovery Platform Providers: Asia Pacific
7.4.1. Harbour BioMed
7.4.1.1. Company Overview
7.4.1.2. Financial Information
7.4.1.3. Antibody Discovery Platforms
7.4.1.3.1. H2L2
7.4.1.3.2. HCAb
7.4.1.4. Patent Information
7.4.1.5. Recent Developments
7.4.1.6. Future Outlook
7.5. Competitiveness Analysis: Antibody Discovery Platforms
7.5.1. Competitiveness Analysis: Library Based Antibody Discovery Platforms
7.5.2. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
8. OPPORTUNITY ANALYSIS
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Antibody Discovery Services Market, 2017-2027 (USD Billion)
8.4. Antibody Discovery Services Market, 2017-2027: Distribution by Regions (USD Billion)
8.4.1. Antibody Discovery Services Market: North America, 2017-2027 (USD Billion)
8.4.2. Antibody Discovery Services Market: Europe, 2017-2027 (USD Billion)
8.4.3. Antibody Discovery Services Market: China, 2017-2027 (USD Billion)
8.4.4. Antibody Discovery Services Market: Rest of the World, 2017-2027 (USD Billion)
8.4.5. Antibody Discovery Services: Market Attractiveness Analysis by Region
8.5. Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process (USD Billion)
8.6. Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods (USD Billion)
8.6.1. Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
8.7. Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated (USD Billion)
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Discovery Services and Platforms: List of Partnerships
9.3.1. Antibody Discovery Services and Platforms: Distribution of Partnerships by Year
9.3.2. Antibody Discovery Services and Platforms: Distribution of Partnerships by Type
9.3.3. Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
10. CASE IN POINT: DRUG DISCOVERY PROCESS OF TOP SELLING ANTIBODIES
10.1. Chapter Overview
10.2. Humira® (Adalimumab)
10.2.1. Drug Overview
10.2.2. Discovery Process and Method
10.3. Remicade® (Infliximab)
10.3.1. Drug Overview
10.3.2. Discovery Process and Method
10.4. Herceptin® (Trastuzumab)
10.4.1. Drug Overview
10.4.2. Discovery Process and Method
10.5. Lucentis® (Ranibizumab)
10.5.1. Drug Overview
10.5.2. Discovery Process and Method
10.6. Simponi® (Golimumab)
10.6.1. Drug Overview
10.6.2. Discovery Process and Method
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Seniority Level of Respondents
11.3. Steps of Antibody Discovery for which Services are Provided
11.4. Antibody Discovery Methods
11.5. Type of Antibody Discovered
11.6. Location of Antibody Discovery Facility / Laboratory
11.7. Likely Market Size
12. CONCLUSION
12.1. High Costs, Process Complexity and Lack of Internal Resources have Led to Increased Outsourcing in Antibody Discovery
12.2. A Number of Platform Providers, With an Aim to Support Antibody Discovery Operations of Drug Developers / CROs, have Emerged
12.3. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs / Technology Providers
12.4. In Order to Maintain a Competitive Edge in the Growing Antibody Discovery Field, the Companies are Developing Innovative Technologies
12.5. Driven by the Rising Demand for Targeted Therapies, the Market is Likely to Witness Continuous Growth in the Coming Decade
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Aaron Sato, Chief Scientific Officer, LakePharma
13.3. Debra Valsamis, Business Development Associate, Antibody Solutions
13.4. Christel Iffland, Vice President, Ligand Pharmaceuticals
13.5. Ignacio Pino, President and CEO, CDI Laboratories
13.6. Jeng Her, CEO, AP Biosciences
13.7. Thomas Schirrmann, CEO and General Manager, YUMAB
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 2.2 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 3.1 Historical Timeline of Antibody Development
Figure 3.2 Basic Structure of Antibody
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Monoclonal Antibodies: Nomenclature
Figure 3.5 Applications of Antibodies
Figure 4.1 An Overview of the Antibody Discovery Process
Figure 4.2 Hybridoma Method
Figure 4.3 Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline: Fully Human Monoclonal Antibody
Figure 4.7 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1 Antibody Discovery Services Providers: Distribution by Geography
Figure 5.2 Antibody Discovery Services Providers: Distribution by Business Operation
Figure 5.3 Antibody Discovery Services Providers: Distribution by Steps Involved in Antibody Discovery
Figure 5.4 Antibody Discovery Services Providers: Antibody Generation Methods
Figure 5.5 Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Figure 5.6 Antibody Discovery Platform Providers: Distribution by Geography
Figure 5.7 Antibody Discovery Platform Providers: Distribution by Antibody Generation Methods
Figure 6.1 Aragen Bioscience: Service Portfolio
Figure 6.2 Aragen Bioscience: Antibody Discovery Services
Figure 6.3 LakePharma: Service Portfolio
Figure 6.4 LakePharma: Antibody Discovery Services
Figure 6.5 Abzena: Service Portfolio
Figure 6.6 Abzena: Annual Revenues, 2013-2016 (EUR Million)
Figure 6.7 ModiQuest Research: Service Portfolio
Figure 6.8 ModiQuest Research: Antibody Discovery Services and Platforms
Figure 6.9 PX’Therapeutics: Service Portfolio
Figure 6.10 ChemPartner: Service Portfolio
Figure 6.11 Viva Biotech: Service Portfolio
Figure 6.12 Viva Biotech: Antibody Discovery Services
Figure 6.13 WuXi Biologics: Service Portfolio
Figure 6.14 WuXi AppTec: Annual Revenues, 2012-Q3 2015 (USD Million),
Figure 6.15 WuXi Biologics: Antibody Discovery Services
Figure 7.1 Ligand Pharmaceuticals: Technology Portfolio
Figure 7.2 Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 7.3 AIMM Therapeutics: Technology Platforms
Figure 7.4 Competitiveness Analysis: Library Based Antibody Discovery Platforms
Figure 7.5 Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 8.1 Antibody Discovery Services Market, 2017-2027: Base Scenario (USD Billion)
Figure 8.2 Antibody Discovery Services Market, 2017 and 2027: Distribution by Regions (%)
Figure 8.3 Antibody Discovery Services Market, 2017-2027: North America, Base Scenario (USD Billion)
Figure 8.4 Antibody Discovery Services Market, 2017-2027: Europe, Base Scenario (USD Billion)
Figure 8.5 Antibody Discovery Services Market, 2017-2027: China, Base Scenario (USD Billion)
Figure 8.6 Antibody Discovery Services Market, 2017-2027: Rest of the World, Base Scenario (USD Billion)
Figure 8.7 Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 8.8 Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Figure 8.9 Antibody Discovery Services Market, 2017, 2022, 2027: Distribution by Antibody Discovery Methods (%)
Figure 8.10 Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 8.11 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 8.12 Antibody Discovery Services Market, 2017 and 2027: Distribution by Nature of Antibody Generated, Base Scenario (%)
Figure 8.13 Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Figure 9.1 Antibody Discovery Services and Platforms: Number of Partnerships by Year (2011-2017)
Figure 9.2 Antibody Discovery Services and Platforms Providers: Distribution by Type of Partnership
Figure 9.3 Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
Figure 11.1 Survey Analysis: Distribution by Geography
Figure 11.2 Survey Analysis: Seniority Levels of Respondents
Figure 11.3 Survey Analysis: Distribution by Steps of Antibody Discovery Services
Figure 11.4 Survey Analysis: Distribution by Antibody Discovery Methods
Figure 11.5 Survey Analysis: Distribution by Type Antibody Discovered
Figure 11.6 Survey Analysis: Location of Antibody Discovery Facility / Laboratory
Figure 11.7 Survey Analysis: Likely Current Market Size
Figure 12.1 Antibody Discovery Services Market: 2017, 2022 and 2027 (USD Billion)
LIST OF TABLES
Table 3.1 Features of Different Isotypes of Antibodies
Table 3.2 Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 3.3 Difference Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 Antibody Discovery: List of Services Providers
Table 5.2 Antibody Discovery Services Providers: Distribution by Type of Business Operation
Table 5.3 Antibody Discovery Service Providers: Distribution by Steps of Antibody Discovery
Table 5.4 Antibody Discovery Services Providers: Distribution by Antibody Generation Method
Table 5.5 Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Table 5.6 List of Antibody Discovery Platform Providers
Table 5.7 Antibody Discovery Platform Providers: Distribution by Antibody Generation Method
Table 5.8 Antibody Discovery Platforms Used for In-house Purposes
Table 6.1 Antibody Discovery Services: List of Companies Profiled
Table 6.2 WuXi AppTec: Funding Instances
Table 7.1 Antibody Discovery Platforms: List of Companies Profiled
Table 7.2 OmniAb® Technology: Key Features
Table 7.3 OmniAb® Technology: Patent Information
Table 7.4 TRIANNI Mouse™: Key Features
Table 7.5 AIMSelect™ Platform: Key Features
Table 7.6 Kymab: Funding Instances
Table 7.7 Kymouse: Key Features
Table 7.8 H2L2 Platform: Key Features
Table 7.9 HCAb Platform: Key Features
Table 9.1 Antibody Discovery Services and Platforms: List of Partnerships
Table 10.1 Top Ten Selling Therapeutic Antibodies, 2016
Table 11.1 Survey Response: Overview of the Participating Companies
Table 11.2 Survey Response: Seniority Level of Respondents
Table 11.3 Survey Response: Steps of Antibody Discovery Services
Table 11.4 Survey Response: Antibody Discovery Methods
Table 11.5 Survey Response: Type of Antibody Discovered
Table 11.6 Survey Response: Location of Antibody Discovery Facility / Laboratory
Table 11.7 Survey Response: Likely Current Market Size
Table 14.1 Approved Monoclonal Antibodies: Development Trend Analysis
Table 14.2 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Table 14.3 Antibody Discovery Services Providers: Distribution by Business Operation
Table 14.4 Antibody Discovery Services Providers: Distribution by Steps Involved in Antibody Discovery
Table 14.5 Antibody Discovery Services Providers: Distribution by Antibody Generation Method
Table 14.6 Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Table 14.7 Antibody Discovery Platform: Distribution by Antibody Generation Methods
Table 14.8 Abzena: Annual Revenues, 2013-H1 2016 (EUR Million)
Table 14.9 WuXi AppTec: Annual Revenues, 2012-Q3 2015 (USD Million)
Table 14.10 Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.11 Antibody Discovery Services Market, 2017-2027: Conservative Scenario (USD Billion)
Table 14.12 Antibody Discovery Services Market, 2017-2027: Base Scenario (USD Billion)
Table 14.13 Antibody Discovery Services Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 14.14 Antibody Discovery Services Market, 2017 and 2027: Distribution by Region (%)
Table 14.15 Antibody Discovery Services Market, 2017-2027: North America, Conservative Scenario (USD Billion)
Table 14.16 Antibody Discovery Services Market, 2017-2027: North America, Base Scenario (USD Billion)
Table 14.17 Antibody Discovery Services Market, 2017-2027: North America, Optimistic Scenario (USD Billion)
Table 14.18 Antibody Discovery Services Market, 2017-2027: Europe, Conservative Scenario (USD Billion)
Table 14.19 Antibody Discovery Services Market, 2017-2027: Europe, Base Scenario (USD Billion)
Table 14.20 Antibody Discovery Services Market, 2017-2027: Europe, Optimistic Scenario (USD Billion)
Table 14.21 Antibody Discovery Services Market, 2017-2027: China, Conservative Scenario (USD Billion)
Table 14.22 Antibody Discovery Services Market, 2017-2027: China, Base Scenario (USD Billion)
Table 14.23 Antibody Discovery Services Market, 2017-2027: China, Optimistic Scenario (USD Billion)
Table 14.24 Antibody Discovery Services Market, 2017-2027: Rest of the World, Conservative Scenario (USD Billion)
Table 14.25 Antibody Discovery Services Market, 2017-2027: Rest of the World, Base Scenario (USD Billion)
Table 14.26 Antibody Discovery Services Market, 2017-2027: Rest of the World, Optimistic Scenario (USD Billion)
Table 14.27 Antibody Discovery Services: Market Attractiveness Analysis by Region
Table 14.28 Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Conservative Scenario (USD Billion)
Table 14.29 Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Table 14.30 Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Optimistic Scenario (USD Billion)
Table 14.31 Antibody Discovery Services Market, 2017, 2022, 2027: Distribution by Antibody Discovery Methods (%)
Table 14.32 Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Conservative Scenario (USD Billion)
Table 14.33 Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Table 14.34 Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Optimistic Scenario (USD Billion)
Table 14.35 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Table 14.36 Antibody Discovery Services Market, 2017 and 2027: Distribution by Nature of Antibody Generated (%)
Table 14.37 Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Conservative Scenario (USD Billion)
Table 14.38 Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Table 14.39 Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Optimistic Scenario (USD Billion)
Table 14.40 Antibody Discovery Services and Platforms: Number of Partnerships by Year (2011-2017)
Table 14.41 Antibody Discovery Service and Platform Providers: Distribution by Type of Partnership
Table 14.42 Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
Table 14.43 Survey Analysis: Distribution by Geography
Table 14.44 Survey Analysis: Seniority Levels of Respondents
Table 14.45 Survey Analysis: Distribution by Steps of Antibody Discovery Services
Table 14.46 Survey Analysis: Distribution by Antibody Discovery Methods
Table 14.47 Survey Analysis: Distribution by Type Antibody Discovered
Table 14.48 Survey Analysis: Location of Antibody Discovery Facility / Laboratory
Table 14.49 Survey Analysis: Likely Current Market Size
Table 14.50 Antibody Discovery Services Market: 2017, 2022 and 2027 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report